These pathways may be inhibited (GSK-3β 16) or activated (Notch1 10, SRC 15) by ASPH in a cell type-specific manner, leading to heterogeneous responses to ASPH inhibition in different cancer cell lines. This evidence concerns the gene SRC and cancer.